Advertisement

Change in PsAID-12 scores in patients continuing or discontinuing anti-TNF treatments in psoriatic arthritis: results from the HUR-BIO biologic registry

  • Umut KalyoncuEmail author
  • Sedat Kiraz
  • Sule Apras Bilgen
  • Omer Karadag
  • Ali Akdogan
  • Levent Kilic
  • Abdulsamet Erden
  • Berkan Armagan
  • Alper Sari
  • Ihsan Ertenli
Original Article
  • 44 Downloads

Abstract

Objective

Psoriatic Arthritis Impact of Disease 12-item questionnaire (PsAID-12) has been developed to be used in psoriatic arthritis in daily practice. The aim of the present study was to assess the change values of PsAID-12 in PsA patients continuing or discontinuing anti-TNF treatment.

Methods

We recruited patients from the Hacettepe University biological database (HUR-BIO). Overall, 70 PsA patients had PsAID-12 score before the initiation of the first anti-TNF treatment. Stopping or switching the anti-TNF treatment due to inefficacy was definitely considered a negative response. Changes were evaluated by the comparison with the baseline PsAID-12 score in compliance with the favorable and unfavorable responses to anti-TNF treatments. The standardized response mean (SRM) was used for determining the response.

Results

Seventy (78.6% female) patients were analyzed and their mean age was 45.5 years (12.0 years). The mean follow-up duration was 18.3 months (12.6 months). At baseline, the mean PsAID-12 score was 6.6 (1.5). Physicians stopped or switched the treatment in 28 patients (40.0%) due to the inefficacy of anti-TNF treatment. The ΔPsAID-12 score was 0.25 (1.71) in the patients discontinuing anti-TNF treatment and 3.52 (2.31) in the patients continuing their anti-TNF treatment (p < 0.001). The SRM scores higher for PsAID-12, particularly in the well response to anti-TNF treatments.

Conclusion

A decrease of 3.5 units in PsAID-12 score shows a favorable response to anti-TNF treatment. Changes in PsAID-12 score had well discrimination capacity for anti-TNF treatments.

Keywords

Anti-TNF treatment Biological registry PsAID-12 Psoriatic arthritis 

Notes

Compliance with ethical standards

The study was approved by the Ethics Committee of Hacettepe University Faculty of Medicine (No. GO 15/788) and was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. Informed consent was obtained from all patients included in the study.

Disclosures

None.

References

  1. 1.
    Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. N Engl J Med 376(10):957–970CrossRefPubMedGoogle Scholar
  2. 2.
    Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewé R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Cañete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75:499–510CrossRefPubMedGoogle Scholar
  3. 3.
    Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW et al (2016) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68:1060–1071PubMedGoogle Scholar
  4. 4.
    Mease PJ (2011) Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken) 63(Suppl 11):S64–S85CrossRefGoogle Scholar
  5. 5.
    Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scrivo R, Maccarone M, Carton L, Otsa K, Sooäär I, Heiberg T, Bertheussen H, Cañete JD, Sánchez Lombarte A, Balanescu A, Dinte A, de Vlam K, Smolen JS, Stamm T, Niedermayer D, Békés G, Veale D, Helliwell P, Parkinson A, Luger T, Kvien TK, On behalf of the EULAR PsAID Taskforce (2014) A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis 73:1012–1019CrossRefPubMedGoogle Scholar
  6. 6.
    Nikiphorou E, Buch MH, Hyrich KL (2017) Biologics registers in RA: methodological aspects, current role and future applications. Nat Rev Rheumatol 13:503–510CrossRefPubMedGoogle Scholar
  7. 7.
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMedGoogle Scholar
  8. 8.
    Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, Jenkinson T (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMedGoogle Scholar
  9. 9.
    Lubrano E, Parsons WJ, Perrotta FM (2016) Assessment of response to treatment, remission, and minimal disease activity in axial psoriatic arthritis treated with tumor necrosis factor inhibitors. J Rheumatol 43:918–923CrossRefPubMedGoogle Scholar
  10. 10.
    Di Carlo M, Becciolini A, Lato V, Crotti C, Favalli EG, Salaffi F (2017) The 12-item Psoriatic Arthritis Impact of Disease Questionnaire: construct validity, reliability, and interpretability in a clinical setting. J Rheumatol 44:279–285CrossRefPubMedGoogle Scholar
  11. 11.
    Queiro R, Canete JD, Montilla C, Abad M, Montoro M, Gomez S et al (2017) Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study. Arthritis Res Ther 19:72CrossRefPubMedGoogle Scholar
  12. 12.
    Holland R, Tillett W, Korendowych E, Cavill C, Waldron N, Brooke M, McHugh NJ (2018) Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire and its potential as a single-item outcome measure in clinical practice. Ann Rheum Dis 77:343–347CrossRefPubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2019

Authors and Affiliations

  • Umut Kalyoncu
    • 1
    Email author
  • Sedat Kiraz
    • 1
  • Sule Apras Bilgen
    • 1
  • Omer Karadag
    • 1
  • Ali Akdogan
    • 1
  • Levent Kilic
    • 1
  • Abdulsamet Erden
    • 1
  • Berkan Armagan
    • 1
  • Alper Sari
    • 1
  • Ihsan Ertenli
    • 1
  1. 1.Department of Internal Medicine, Division of RheumatologyHacettepe University Faculty of MedicineAnkaraTurkey

Personalised recommendations